Clinical Trials Logo

Clinical Trial Summary

This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.


Clinical Trial Description

The purpose of this study is to examine the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). There are currently very limited data available about the use of CGRP receptor antagonists in this population, resulting in difficulty obtaining prior authorization to use ubrogepant in patients currently treated with CGRPmAbs. Questions remain as to whether these patients, whose CGRP or CGRP receptors are suppressed, will experience the same safety and efficacy results as patients without such suppression by CGRPmAbs. This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial. Primary Objective: To evaluate the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). Primary Endpoint: - Pain freedom at 2 hours. - Freedom from most bothersome symptom at 2 hours Secondary Objectives: To assess improvements with the addition of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). Secondary Endpoint: - Pain relief at 2 hours (this is different from pain freedom: moderate to severe pain reduced to mild or no pain) - Percentage of patients with sustained pain relief from 2-24 hours after initial dose - Percentage of patients with sustained pain freedom from 2-24 hours after initial dose - Pain relief at 2 hours after 2nd dose - Percentage of patients with sustained pain relief from 2-24 hours after 2nd dose - Percentage of patients with sustained pain freedom from 2-24 hours after 2nd dose ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05503082
Study type Interventional
Source Chicago Headache Center & Research Institute
Contact Melody Smith
Phone 7739351000
Email msmith@chicagoheadache.com
Status Recruiting
Phase Phase 4
Start date September 6, 2022
Completion date September 2024

See also
  Status Clinical Trial Phase
Completed NCT04905654 - Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura N/A
Completed NCT04111484 - Adrenomedullin Effect on Migraine Without Patients N/A
Recruiting NCT04091789 - Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea Phase 2
Completed NCT03337620 - Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine Phase 3
Completed NCT02259387 - Adolescents With Migraine: What's Stress Got To Do With It?
Completed NCT05658185 - Migraine Difficult to Treat: the Importance of Psychological Care in the Chronic Patient N/A
Completed NCT05001399 - Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain N/A
Completed NCT03490500 - Using the S100B Protein for Emergency Headache Management Care (S100)
Completed NCT03075020 - Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura. N/A
Recruiting NCT03472092 - Mind and Body Approaches to Pain Reduction in Youth With Migraine Phase 2
Enrolling by invitation NCT04976985 - Osteopathic Manipulative Treatment and Migraine Headaches N/A
Active, not recruiting NCT04372264 - Intravenous Paracetamol, Dexketoprofen and Ibuprofen in the Treatment of Acute Migraine Attack Headache Phase 4
Recruiting NCT04623203 - The Prognosis of Migraine and Tension-Type Headache in Children and Adolescents
Completed NCT04577443 - The Effect of Adenosine on Cranial Hemodynamic, Headache and Migraine Induction Properties. N/A
Completed NCT03560024 - The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers N/A
Completed NCT03228355 - Headache Inducing Effect of Cromakalim in Migraine Patients N/A
Completed NCT02438553 - Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain N/A
Recruiting NCT03577548 - Influence of Main Psychological and Social Factors on Primary Headaches
Recruiting NCT04715685 - Mind Body Balance for Pediatric Migraine N/A
Completed NCT05853900 - Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Phase 3